AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33146854 — intervention group
Group type: EXPERIMENTAL
Intervention: sTREM-1
Number of subjects: 143
Study 33146854 — intervention group
Group type: EXPERIMENTAL
Intervention: presepsin
Number of subjects: 143
Study 33146854 — intervention group
Group type: EXPERIMENTAL
Intervention: sTREM-1 and presepsin combined with CLIF-SOFA score
Number of subjects: 143
Study 33146854 — intervention group
Group type: COMPARATOR
Intervention: Other biomarkers (WBC, PCT, CRP)
Number of subjects: 143
Study 33146924 — intervention group
Group type: COMPARATOR
Intervention: Patients without DM
Number of subjects: 8968
Study 33146924 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM
Number of subjects: 8968
Study 33146953 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment on HT-7 for 5 weeks
Number of subjects: 30
Study 33147086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative stigma experiences
Number of subjects: 251
Study 33147086 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma from family members and acts of overt discrimination
Number of subjects: 251
Study 33147086 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender analysis
Number of subjects: 251
Study 33147119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential imaging with dual tracers
Number of subjects: 0
Study 33147119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential use of PET tracers
Number of subjects: 0
Study 33147165 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-triage web application
Number of subjects: 735419
Study 33147283 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D regimen treatment
Number of subjects: 41
Study 33147426 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation Intentions (II) training protocol
Number of subjects: 0
Study 33147613 — intervention group
Group type: EXPERIMENTAL
Intervention: RA patients with MTX only or with other medications
Number of subjects: 102
Study 33147613 — intervention group
Group type: EXPERIMENTAL
Intervention: RA patients with varying disease activity (DAS28 and CRP levels)
Number of subjects: 102
Study 33148185 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Activation Measurement (PAM)
Number of subjects: 605
Study 33148185 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) measured with a 5-item Likert scale
Number of subjects: 605
Study 33148185 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of covariance (ANCOVA)
Number of subjects: 605
Study 33148190 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for hospital staff (lectures, workshops, and small projects to increase person-centeredness).
Number of subjects: 99
Study 33148216 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish BESTest
Number of subjects: 30
Study 33148216 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish Mini-BESTest
Number of subjects: 30
Study 33148216 — intervention group
Group type: EXPERIMENTAL
Intervention: BESTest and Mini-BESTest total scores by sex
Number of subjects: 30
Study 33148235 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 µg epinephrine applied into the test well
Number of subjects: 21
Study 33148235 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline applied into the control well
Number of subjects: 21
Study 33148261 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Device (certolizumab pegol self-injection)
Number of subjects: 0
Study 33148277 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin administration
Number of subjects: 340
Study 33148277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin administration
Number of subjects: 340
Study 33148277 — intervention group
Group type: EXPERIMENTAL
Intervention: IS and hyperglycemia without treatment
Number of subjects: 340
Study 33148277 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia without IS
Number of subjects: 340
Study 33148277 — intervention group
Group type: COMPARATOR
Intervention: IS without hyperglycemia
Number of subjects: 340
Study 33148277 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 340
Study 33148330 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-TMZ (concomitant temozolomide and radiotherapy)
Number of subjects: 52
Study 33148673 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986178 monotherapy (20-320 mg)
Number of subjects: 165
Study 33148673 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986178 plus nivolumab (240-480 mg)
Number of subjects: 165
Study 33148673 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab monotherapy (240-480 mg)
Number of subjects: 165
Study 33148673 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986178 plus ipilimumab (1-3 mg/kg)
Number of subjects: 165
Study 33148673 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986178 plus nivolumab plus ipilimumab
Number of subjects: 165
Study 33148693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four cycles then nivolumab 3 mg/kg every 2 weeks until progression or a maximum of 20 cycles.
Number of subjects: 57
Study 33148693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab combination therapy
Number of subjects: 57
Study 33148732 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1532
Study 33148961 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week self-management program
Number of subjects: 62
Study 33148977 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 infection in SOT recipients
Number of subjects: 0
Study 33148977 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant activity during the pandemic
Number of subjects: 0
Study 33148977 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment strategies and vaccinations for COVID-19
Number of subjects: 0
Study 33148993 — intervention group
Group type: EXPERIMENTAL
Intervention: MSMW
Number of subjects: 0
Study 33148993 — intervention group
Group type: EXPERIMENTAL
Intervention: MSMW-T
Number of subjects: 0
Study 33148993 — intervention group
Group type: COMPARATOR
Intervention: MSMO
Number of subjects: 0
Study 33149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Job demand
Number of subjects: 3142
Study 33149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Overinvestment
Number of subjects: 3142
Study 33149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort-reward imbalance (ERI)
Number of subjects: 3142
Study 33149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Job strain
Number of subjects: 3142
Study 33149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Isostrain
Number of subjects: 3142
Study 33149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Job demand-control-support model
Number of subjects: 3142
Study 33149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort-reward imbalance model
Number of subjects: 3142
Study 33149182 — intervention group
Group type: EXPERIMENTAL
Intervention: gemigliptin
Number of subjects: 5113
Study 33149400 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF (GI)
Number of subjects: 60
Study 33149400 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF with amorphous calcium phosphate (ACP) (GII)
Number of subjects: 60
Study 33149400 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF with casein phosphopeptides - amorphous calcium phosphate (CPP-ACP) (GIII)
Number of subjects: 60
Study 33149768 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus endocrine therapy (ET)
Number of subjects: 306
Study 33149768 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus endocrine therapy (ET)
Number of subjects: 306
Study 33150137 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions
Number of subjects: 92509
Study 33150137 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 92509
Study 33150319 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted group therapy (0.3-0.36 mg/kg po) with 8-10 group therapy visits and one psilocybin administration visit
Number of subjects: 18
Study 33150319 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted group therapy
Number of subjects: 18
Study 33150320 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-DT vaccine (one or two doses)
Number of subjects: 285
Study 33150320 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-DT vaccine (two doses)
Number of subjects: 285
Study 33150320 — intervention group
Group type: COMPARATOR
Intervention: Comparator vaccine
Number of subjects: 285
Study 33150320 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-DT vaccine
Number of subjects: 285
Study 33150322 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 12123
Study 33150325 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable mebendazole tablet
Number of subjects: 397
Study 33150325 — intervention group
Group type: COMPARATOR
Intervention: Solid mebendazole tablet
Number of subjects: 397
Study 33150375 — intervention group
Group type: EXPERIMENTAL
Intervention: N95/PAPR mask
Number of subjects: 20614
Study 33150375 — intervention group
Group type: COMPARATOR
Intervention: Surgical/other masks
Number of subjects: 20614
Study 33150375 — intervention group
Group type: COMPARATOR
Intervention: No mask
Number of subjects: 20614
Study 33150375 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall seropositivity
Number of subjects: 20614
Study 33150388 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 348
Study 33150388 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 348
Study 33150390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1250 mg/day for 6 months
Number of subjects: 4
Study 33150390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 4
Study 33150746 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20
Study 33150753 — intervention group
Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 366
Study 33150753 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + CTI
Number of subjects: 366
Study 33150779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fish oil capsules
Number of subjects: 40
Study 33150779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33150834 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine, etoposide, and cyclophosphamide (CloEC)
Number of subjects: 7
Study 33150947 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load trials (8 letters)
Number of subjects: 32
Study 33150947 — intervention group
Group type: EXPERIMENTAL
Intervention: Right dlPFC activity during high-load trials
Number of subjects: 32
Study 33150947 — intervention group
Group type: EXPERIMENTAL
Intervention: dlPFC activity during threat
Number of subjects: 32
Study 33150947 — intervention group
Group type: COMPARATOR
Intervention: Overall WM performance
Number of subjects: 32
Study 33151515 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective caregiver assessments of consciousness
Number of subjects: 12
Study 33151515 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective caregiver assessments of pain
Number of subjects: 12
Study 33151515 — intervention group
Group type: COMPARATOR
Intervention: Objective neurophysiological measures of consciousness and pain
Number of subjects: 12
Study 33151636 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment
Number of subjects: 530
Study 33151978 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent surgical team for wound closure
Number of subjects: 144
Study 33151978 — intervention group
Group type: COMPARATOR
Intervention: Main surgical team for wound closure
Number of subjects: 144
Study 33152061 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of Mediterranean Diet Adherence Screener score
Number of subjects: 1301
Study 33152061 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining or improving DAI over follow-up (over-resilience)
Number of subjects: 1301
Study 33152061 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintentional weight loss as acute stressor
Number of subjects: 1301
Study 33152061 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization as acute stressor
Number of subjects: 1301
Study 33152282 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiogenesis inhibitors
Number of subjects: 0
Study 33152715 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33152759 — intervention group
Group type: EXPERIMENTAL
Intervention: KMT2D mutations
Number of subjects: 0
Study 33152759 — intervention group
Group type: COMPARATOR
Intervention: Wild-type KMT2D
Number of subjects: 0
Study 33153453 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery protocols (ERPs) for THA/TKA
Number of subjects: 186
Study 33153453 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 186
Study 33153461 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Multimodal Intervention (MMI) for 24 weeks
Number of subjects: 390
Study 33153503 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep transcranial magnetic stimulation (dTMS); specific dosage and duration not available
Number of subjects: 0
Study 33153503 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33153580 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated carotid artery plaques (CAP) in patients with cryptogenic stroke (CS) ipsilateral to the infarct
Number of subjects: 196
Study 33153580 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated carotid artery plaques (CAP) in patients with cryptogenic stroke (CS) contralateral to the infarct
Number of subjects: 196
Study 33153580 — intervention group
Group type: COMPARATOR
Intervention: Complicated carotid artery plaques (CAP) in patients with cryptogenic stroke (CS) compared to cardioembolic or small vessel stroke (CES/SVS)
Number of subjects: 196
Study 33153580 — intervention group
Group type: COMPARATOR
Intervention: Complicated carotid artery plaques (CAP) in patients with cryptogenic stroke (CS) compared to large artery stroke (LAS)
Number of subjects: 196
Study 33153580 — intervention group
Group type: COMPARATOR
Intervention: Lipid-rich and/or necrotic cores in ipsilateral CAP in patients with cryptogenic stroke (CS) compared to cardioembolic or small vessel stroke (CES/SVS)
Number of subjects: 196
Study 33153629 — intervention group
Group type: EXPERIMENTAL
Intervention: lenzilumab 600 mg intravenously for three doses
Number of subjects: 39
Study 33153629 — intervention group
Group type: COMPARATOR
Intervention: untreated (control)
Number of subjects: 39
Study 33153629 — intervention group
Group type: EXPERIMENTAL
Intervention: lenzilumab
Number of subjects: 39
Study 33153727 — intervention group
Group type: EXPERIMENTAL
Intervention: Apararenone (320 mg on day 2, 20 mg/d on days 3-15) with Midazolam (2 mg on days 1 and 15)
Number of subjects: 56
Study 33153727 — intervention group
Group type: EXPERIMENTAL
Intervention: Apararenone (40 mg/d on days 8-11, 10 mg/d on days 12-27) with Warfarin (25 mg on days 1 and 21)
Number of subjects: 56
Study 33153727 — intervention group
Group type: EXPERIMENTAL
Intervention: Apararenone (160 mg on day 11, 10 mg/d on days 12-28) with Digoxin (0.5 mg on days 1 and 24)
Number of subjects: 56
Study 33153960 — intervention group
Group type: EXPERIMENTAL
Intervention: OGTT (Oral Glucose Tolerance Test)
Number of subjects: 131
Study 33154028 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study 33154028 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 0
Study 33154049 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory function parameters
Number of subjects: 500
Study 33154049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia-related mortality
Number of subjects: 500
Study 33154049 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 500
Study 33154049 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal data for prognostic models
Number of subjects: 500
Study 33154057 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine (nab-P+Gem) chemotherapy plus split-course SBRT
Number of subjects: 0
Study 33154417 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal volatile organic compounds (VOCs) analysis
Number of subjects: 0
Study 33154417 — intervention group
Group type: COMPARATOR
Intervention: Control group (children discharged alive)
Number of subjects: 0
Study 33154826 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with low pre-therapeutic serum GGT levels (< 29 U/L)
Number of subjects: 129
Study 33154826 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC) with high pre-therapeutic serum GGT levels (≥ 29 U/L)
Number of subjects: 129
Study 33154826 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 129
Study 33154953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal application of nan
Number of subjects: 0
Study 33155163 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-5190457
Number of subjects: 47
Study 33155938 — intervention group
Group type: EXPERIMENTAL
Intervention: macitentan 10 mg/day
Number of subjects: 44
Study 33155938 — intervention group
Group type: COMPARATOR
Intervention: bosentan 250 mg/day
Number of subjects: 44
Study 33156107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 120
Study 33156244 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Alcohol Concentration (BAC) screening
Number of subjects: 300
Study 33156244 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAFFT screening
Number of subjects: 300
Study 33156244 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine Drug Screen (UDS)
Number of subjects: 300
Study 33156398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic Flexible Endoscopic Evaluation of Swallowing (FEES) examination
Number of subjects: 213
Study 33156398 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate and multivariable analyses
Number of subjects: 213
Study 33156465 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically relevant postoperative pancreatic fistula (CR-POPF)
Number of subjects: 283
Study 33156465 — intervention group
Group type: COMPARATOR
Intervention: No CR-POPF
Number of subjects: 283
Study 33156465 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-POPF
Number of subjects: 283
Study 33156829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher reward
Number of subjects: 0
Study 33156829 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-related activity
Number of subjects: 0
Study 33156829 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous responses
Number of subjects: 0
Study 33156849 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed mobilization (≥36h)
Number of subjects: 306
Study 33156849 — intervention group
Group type: COMPARATOR
Intervention: Early mobilization (<36h)
Number of subjects: 306
Study 33156982 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) 100/62.5/25µg
Number of subjects: 10355
Study 33156982 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Furoate/Vilanterol (FF/VI) 100/25µg
Number of subjects: 10355
Study 33156982 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25µg
Number of subjects: 10355
Study 33156982 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Number of subjects: 10355
Study 33156982 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Furoate/Vilanterol (FF/VI) and Umeclidinium/Vilanterol (UMEC/VI)
Number of subjects: 10355
Study 33157081 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of COVID-19 severity in patients with type 2 diabetes
Number of subjects: 0
Study 33157979 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT-PET imaging
Number of subjects: 0
Study 33158499 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative troponin increases
Number of subjects: 114
Study 33158766 — intervention group
Group type: EXPERIMENTAL
Intervention: SADI-S
Number of subjects: 42
Study 33158766 — intervention group
Group type: COMPARATOR
Intervention: DS
Number of subjects: 42
Study 33158801 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly processed (HP) foods
Number of subjects: 46
Study 33158801 — intervention group
Group type: EXPERIMENTAL
Intervention: Savory food intake in the HP condition
Number of subjects: 46
Study 33158801 — intervention group
Group type: COMPARATOR
Intervention: Minimally processed (MP) foods
Number of subjects: 46
Study 33158819 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention (INT) which includes pharmacotherapy and a hybrid of behavioural support delivered by trained healthcare practitioners (HCPs) and a web-based application.
Number of subjects: 5
Study 33158819 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) which consists of standard community/hospital based NHS smoking support.
Number of subjects: 5
Study 33158947 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33159213 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of treatment at the time of diagnosis in males with X-linked Alport syndrome
Number of subjects: 0
Study 33159213 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of treatment at the time of diagnosis in males and females with autosomal recessive Alport syndrome
Number of subjects: 0
Study 33159213 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting treatment at the onset of microalbuminuria in females with X-linked Alport syndrome
Number of subjects: 0
Study 33159213 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting treatment at the onset of microalbuminuria in males and females with autosomal dominant Alport syndrome
Number of subjects: 0
Study 33159216 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg IV weekly and Erlotinib 100 mg orally daily (RP2D)
Number of subjects: 44
Study 33159216 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 15 mg IV weekly and Erlotinib 100 mg orally daily (starting dose)
Number of subjects: 44
Study 33159216 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus and Erlotinib combination
Number of subjects: 44